Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare genetic disorders. The company is particularly focused on conditions such as Prader-Willi syndrome, and their lead candidate, DCCR (Diazoxide Choline) Extended-Release tablets, is currently in Phase 3 clinical trials. Soleno is inspired by the needs of patients and families living with rare diseases and aims to deliver effective treatment options to enhance their quality of life. The company is dedicated to advancing research and developing treatments for diseases with unmet medical needs, thereby contributing to shareholder value while improving patient outcomes.
Biopharmaceuticals β’ Therapeutics for the treatment of rare diseases β’ Pharmaceuticals
October 31
Key sales leader for rare disease therapeutics at Soleno Therapeutics.
πΊπΈ United States β Remote
π΅ $230k - $260k / year
π° $975k Grant on 2023-05
β° Full Time
π΄ Lead
π Director